
| 10.1016/j.psychres.2020.113198
http://scihub22266oqcxt.onion/10.1016/j.psychres.2020.113198
 32535509!�!32535509
Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32535509&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
|  
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32535509.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117
Psychiatry+Res 2020 ; 291 (�): 113198 Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
|
COVID-19, interferons, and depression: A commentary #MMPMID32535509Shader RIPsychiatry Res 2020[Sep]; 291 (�): 113198 PMID32535509show ga
An option currently being explored for the treatment of COVID-19 is the use of interferons (INFs), either alone or in combination with other antiviral agents. INFs are known to shift the metabolism of tryptophan (TRP) away from its role as a precursor of serotonin. For some patients, reduction in TRP levels may either expose an underlying vulnerability to depression or trigger a de novo episode of depression. This Commentary discusses the pathway involved and recommends in-hospital augmentation with foods or supplements that increase TRP levels for COVID-19 patients treated with INFs. Selective serotonin reuptake inhibitors may also be tried if the depressive symptomatology is not short-lived.|*Betacoronavirus[MESH]|COVID-19[MESH]|Coronavirus Infections/*metabolism/*psychology[MESH]|Depression/*metabolism/psychology[MESH]|Humans[MESH]|Interferons/*metabolism[MESH]|Pandemics[MESH]|Pneumonia, Viral/*metabolism/*psychology[MESH]|SARS-CoV-2[MESH]|Serotonin/metabolism[MESH]
  
DeepDyve Pubget Overpricing | 
|